Patents by Inventor Travis Biechele

Travis Biechele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cysteine mutated antibodies for conjugation
    Patent number: 11938194
    Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 26, 2024
    Assignee: SEAGEN INC.
    Inventors: Andrew Waight, Chris Leiske, Travis Biechele, Django Sussman, Patrick Burke, Jocelyn Leiske
  • Glypican 3 antibodies and conjugates thereof
    Patent number: 11819553
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 21, 2023
    Assignee: Seagen Inc.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • CYSTEINE MUTATED ANTIBODIES FOR CONJUGATION
    Publication number: 20220175947
    Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
    Type: Application
    Filed: February 28, 2018
    Publication date: June 9, 2022
    Applicant: SEAGEN INC.
    Inventors: Andrew WAIGHT, Chris LEISKE, Travis BIECHELE, Django SUSSMAN, Patrick BURKE, Jocelyn LEISKE
  • Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
    Patent number: 11191771
    Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 7, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
  • GLYPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
    Publication number: 20210361776
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 25, 2021
    Applicant: Seagen Inc.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
    Patent number: 11027021
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm
  • COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH FLT3 INHIBITORS
    Publication number: 20190262354
    Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
    Type: Application
    Filed: June 8, 2017
    Publication date: August 29, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
  • COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS
    Publication number: 20190076549
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 14, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm